Freenome, Inc. (FRNM) is a Brisbane, California-based early cancer detection company that develops blood-based (liquid biopsy) screening tests. The company went public in July 2026 through a business combination with Perceptive Capital Solutions Corp., raising roughly $310 million.
Because the company is newly public, analyst coverage is recent and focused. Five firms initiated coverage in August 2026 with price targets between $17 and $21. Guggenheim set the high at $21, while Leerink Partners set an $18 target and Jefferies, BTIG, and TD Cowen each set a $17 target. The arithmetic mean of these five targets is exactly $18, which serves as the central target used throughout this article. All five ratings are Buy or Outperform, producing a consensus of "Strong Buy" on aggregator platforms.
The reasoning is broadly similar but the magnitude of enthusiasm differs. Guggenheim described a "scientifically robust company" with a "compelling" risk/reward, while TD Cowen's Dan Brennan highlighted a sales ramp from about $107 million in 2026 toward $1 billion by 2035. Jefferies' Tycho Peterson emphasized an "asset-light" commercial model and reimbursement catalysts, and BTIG's Mark Massaro cited a roughly $100 billion addressable market. The tight $17–$21 range reflects agreement on the story, with differences mostly over near-term commercial traction and cash needs.
As of the most recent verified close, FRNM traded near $12.77, within a 52-week range of $9.95 to $17.50. Reaching $18 would require a gain of about 41% from that level—a substantial move by most standards.
The path toward the target depends primarily on execution rather than broad market direction. Freenome has already secured U.S. Food and Drug Administration (FDA) approval for SimpleScreen CRC, its colorectal cancer screening test, and began commercialization in the third quarter of 2026. Analysts expect a sequence of catalysts: expansion of SimpleScreen CRC adoption, the launch of a lung screening test, and eventual multi-cancer detection products. Each milestone expands the revenue base that currently stands at roughly $35 million in trailing twelve-month revenue against a net loss of about $235 million.
Several verified factors support a higher stock price target. Freenome's partnerships with Abbott (ABT) and Roche provide distribution scale and milestone economics; Jefferies cited up to $700 million in potential milestones and royalties tied to the Abbott agreement, while Leerink noted more than $170 million in milestone payments due through 2028.
Reimbursement progress is another catalyst. SimpleScreen CRC is included in American Cancer Society guidelines, and analysts expect commercial insurer coverage to build ahead of a U.S. Preventive Services Task Force review expected in late 2027 or 2028. A lung screening test and a multi-cancer early detection (MCED) test would meaningfully expand the addressable market. Cash of about $102 million on the balance sheet also provides near-term runway.
The principal obstacle is financial: Freenome is not profitable, with a trailing EPS (earnings per share) of roughly -$2.04 and high cash burn. TD Cowen flagged projected capital raises of around $1 billion over time, which could dilute existing shareholders. There is also limited visibility on pipeline products that have not yet launched.
Competition is meaningful. Guardant Health (GH) markets the Shield blood-based colorectal cancer test, and Exact Sciences (EXAS) is a leader in colorectal cancer screening. Leerink specifically noted uncertainty over how much CRC testing revenue Freenome will ultimately capture through its Abbott collaboration, and the risk that SimpleScreen CRC competes against Guardant's established assay.
Technically, FRNM has traded between roughly $9.95 and $17.50 over the past year. The $17.50 level marks a prior high and acts as a notable resistance zone, sitting just below the $18 target. The 200-day moving average has been near the $12.50 area, a level the stock has tested as support in recent sessions. A sustained move above $17.50 would be an important technical step toward the $18 objective.
Analyst price targets typically reflect a roughly 12-month research horizon, though the specific horizon for these initiations was not uniformly disclosed. Because all five targets were set in August 2026, investors should watch for whether analysts update them as commercial data emerges. The next confirmed earnings report is scheduled for November 10, 2026.
Key items to monitor include quarterly adoption of SimpleScreen CRC, lung test launch timing, reimbursement decisions, FDA submissions, cash position and any financing announcements, and the competitive landscape in blood-based cancer screening.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, event-driven name like Freenome, these signals can help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening. Explore the AI Daily Buy/Sell Signals to see how the tool frames the current setup.
Can Freenome (FRNM) reach $18? The question reflects the arithmetic mean of five analyst price targets ranging from $17 to $21, requiring a gain of about 41% from the latest price near $12.77. Support comes from FDA approval of its lead test, deep partnerships with Abbott and Roche, reimbursement momentum, and a broad cancer-screening pipeline. The main obstacles are ongoing losses, high cash burn and potential dilution, pipeline uncertainty, and competition from Guardant Health and Exact Sciences. The tight analyst range signals conviction, but a mean target is a statistical midpoint—not a guarantee. Investors should monitor commercialization data, reimbursement decisions, and financing activity as the company works to convert a promising platform into sustained revenue growth.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
| Ticker / NAME | Correlation To FRNM | 1D Price Change % |
|---|---|---|
| FRNM | 100% | -2.95% |
| Medical Specialties category (43 stocks) | 5% Poorly correlated | -3.31% |
| Medical Specialties category (43 stocks) | 5% Poorly correlated | -3.31% |